What's Going On With Recursion Pharmaceuticals Stock?
What's Going On With Recursion Pharmaceuticals Stock?
"Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers," said Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Tuesday, pulling back after gaining more than 16% over the past week. Here's a look at what's going on.
遞歸製藥公司（納斯達克：RXRX）的股價在週二下跌，此前在過去一週中上漲了超過16%。以下是當前情況的概述。
What To Know: Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special Conference in Cancer Research after the market close on Monday.
要知道的是：遞歸在週二舉行了一個網絡研討會，討論REC-617的1/2期研究結果，這是一種選擇性CDK7抑制劑，針對晚期實體瘤。結果在週一市場關閉後的AACR抗癌醫藥特別會議上進行了報告。
The company said REC-617 demonstrated dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic (PD) biomarker modulation. Recursion also confirmed partial response observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer. An additional four patients demonstrated a best response of stable disease for up to six months of treatment.
該公司表示，REC-617表現出劑量線性藥代動力學，具有快速吸收和強大的藥效學（PD）生物標誌物調節。遞歸還確認在對鉑耐藥卵巢癌患者的單藥劑量遞增過程中觀察到部分反應。另有四名患者在接受最多六個月的治療後顯示出穩定疾病的最佳反應。
"Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers," said David Hallett, chief scientific officer of Recursion Pharmaceuticals.
遞歸製藥的首席科學官大衛·哈萊特表示："細胞週期失調和轉錄'上癮'都是許多侵襲性癌症的標誌。"
"By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level."
他說："通過抑制CDK7，我們有潛力同時針對這兩種機制，同時精細調整治療指數。利用我們的精密設計平台，我們創造了一種具有快速口服吸收的分子，以減少胃腸道組織暴露，適合的半衰期來管理副作用，並且目標參與覆蓋IC80水平。"
Recursion said it plans to continue monotherapy dose escalation and initiate combination studies in the first half of 2025. The company expects to present additional REC-617 data at future medical meetings.
遞歸表示計劃繼續單藥劑量遞增，並在2025年上半年啓動組合研究。該公司預計將在未來的醫療會議上展示更多REC-617數據。
Recursion shares traded higher last week after the company announced that the first patient was dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.
遞歸的股票上週上漲，此前該公司宣佈其REC-1245的1/2期臨床試驗中的首名患者接受了給藥，這是一種治療生物標誌物富集實體瘤和淋巴瘤的新化學實體。
REC-1245 is an alternative target for modulating DNA damage response pathways, and was developed with Recursion's AI-enabled drug discovery platform.
REC-1245是調節DNA損傷反應通路的替代靶點，並且是通過遞歸的人工智能驅動的藥物發現平台開發的。
It's worth noting that Nvidia reported investments in multiple companies, including Recursion, in a 13-F filing with the SEC earlier this year. According to the company's most recent filing on Nov. 14, Recursion is Nvidia's third-largest investment after Arm Holdings and Applied Digital.
值得注意的是，英偉達在今年早些時候向SEC提交的13-F文件中報告了對多家公司的投資，包括Recursion。根據公司在11月14日的最新文件，Recursion是英偉達僅次於Arm Holdings和Applied Digital的第三大投資。
RXRX Price Action: Recursion Pharmaceuticals shares are up 16.64% over the past week. The stock was down 1.95% at $8.10 at the time of publication Tuesday, per Benzinga Pro.
RXRX價格走勢: Recursion Pharmaceuticals的股價在過去一週上漲了16.64%。根據Benzinga Pro的數據，週二在發佈時該股下跌了1.95%，報$8.10。
Photo: Shutterstock.
圖片：Shutterstock。
譯文內容由第三人軟體翻譯。
